Australia markets open in 5 hours 42 minutes

Oculis Holding AG (OCS)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
11.61+0.30 (+2.65%)
As of 02:04PM EDT. Market open.

Oculis Holding AG

Bahnhofstrasse 7
Zug 6300
41 41 711 9325

Full-time employees36

Key executives

NameTitlePayExercisedYear born
Dr. Riad Sherif M.B.A., M.D.CEO & DirectorN/AN/A1968
Ms. Sylvia CheungChief Financial OfficerN/AN/A1975
Dr. Ramin Tadayoni M.D., Ph.D.Chief Scientific OfficerN/AN/AN/A
Ms. Virginia R. DeanChief Human Resources OfficerN/AN/A1967
Dr. Bastian Dehmel M.D.Chief Development OfficerN/AN/A1971
Mr. Páll Ragnar JóhannessonChief Business OfficerN/AN/A1982
Ms. Rebecca WeilChief Commercial OfficerN/AN/AN/A
Dr. Snehal Shah Pharm.D.President of Research & DevelopmentN/AN/AN/A
Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.

Corporate governance

Oculis Holding AG’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.